Atrial Fibrillation: Clinical Update and Review, Paradigm Shift of Rhythm Control

Abstract

Background: Atrial fibrillation is a worldwide burden to clinical healthcare, characterized by loss of normal sinus node pacemaker activity due to rapid electrical impulses from multiple atrial foci, resulting in ineffective atrial contraction and impaired blood pumping. Although no single etiology exists, atrial fibrillation is associated with cardiovascular risk factors such as hypertension and diabetes mellitus. atrial fibrillation increases the risk of stroke, myocardial infarction, heart failure and mortality. This review discusses the definition, classification, pathophysiology, diagnosis, and contemporary management strategies. 

Main: Atrial fibrillation is commonly classified according European Society of Cardiology to its temporal pattern into first-diagnosed, paroxysmal, persistent, long-standing persistent, and permanent atrial fibrillation. The American Heart Association further recognizes its progression through stages ranging from at-risk and pre- atrial fibrillation states to permanent atrial fibrillation. The American Heart Association’s framework and European Society of Cardiology pathway share a unified principle of management: optimizing cardiovascular risk factors, preventing stroke, and controlling symptoms. Both emphasize integrated care, where comorbidity management and anticoagulation underpin therapy, while symptom control is tailored to individual patient needs. 

Finding: Emerging evidence supports catheter ablation in newly diagnosed atrial fibrillation, including patients with mild heart failure, due to improved long-term cardiovascular outcomes and reduced hospitalizations. AP30663, a novel atrial-selective KCa2 inhibitor, has shown promising antiarrhythmic effects in preclinical studies and was conducted in phase II evaluation. Lifestyle and risk-factor modification, including weight reduction, exercise, smoking cessation, alcohol moderation, and control of hypertension and diabetes, are essential in slowing atrial fibrillation’s progression. 

Conclusion: Contemporary management increasingly emphasizes early rhythm control, particularly catheter ablation, while novel agents such as AP30663 show promising potential. Long-term management also depends heavily on lifestyle and cardiovascular risk-factor modification.